Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201878242> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W3201878242 endingPage "S1132" @default.
- W3201878242 startingPage "S1132" @default.
- W3201878242 abstract "Preliminary studies have characterized potential adverse effects associated with COVID-19 vaccination in pts with cancer. However, biological characterization of vaccine response has yet to be performed. Eligible pts with advanced GU cancers (metastatic/unresectable prostate, bladder and renal cell carcinoma [RCC]) and had not yet received COVID-19 vaccination. Pts were consented to receive sequential blood draws prior to vaccination and at landmarks of 2, 6, and 12 mos following vaccination. Pts on systemic treatment had additional blood draws coinciding with their first 3 cycles of therapy following vaccination. Ab titers to SARS-CoV-2 were quantified via ELISA and reported as an immune status ratio (ISR). RNA was extracted from PBMC aliquots, converted into cDNA and TCR α/β sequences were selectively amplified. TCR abundance and homology clustering was performed using custom scripts. As of May 14, 2021, 130 pts had consented to the study of whom 126 pts submitted baseline (BL) specimens. The current analysis focuses on 56 pts who submitted cycle 1 (C1) specimens. Among these, 29, 26, and 1 pts had RCC, prostate and bladder cancer, respectively; 19 were on checkpoint inhibitor (CPI)-based regimens while 37 were on non-CPI regimens. BNT162b2 (Pfizer) was the most commonly administered vaccine in the cohort (n=29), followed by mRNA-1273 (Moderna; n=26). COVID-19 Ab titers increased significantly from BL to C1 across the cohort from 0.19 (interquartile range [IQR] 0.12-0.18) to 4.37 (IQR 0.2-6.60; P<0.0001). However, 8/56 pts (14.3%) receiving CPI-based regimens and 8/56 pts (14.3%) receiving non-CPI-based regimens were noted to have negative Ab titers after a median of 18 and 35 days following initial vaccination, respectively. No significant difference was observed in the increase from BL to C1 in pts receiving CPI vs non-CPI-based regimens. Specimen collection is ongoing; updated Ab titer data and TCR sequencing data will be presented. Our data prompt concern for delayed or insufficient COVID-19 Ab response in a subset of pts with advanced GU cancers." @default.
- W3201878242 created "2021-10-11" @default.
- W3201878242 creator A5005719127 @default.
- W3201878242 creator A5012361531 @default.
- W3201878242 creator A5020250473 @default.
- W3201878242 creator A5021244561 @default.
- W3201878242 creator A5028660468 @default.
- W3201878242 creator A5032713796 @default.
- W3201878242 creator A5032724752 @default.
- W3201878242 creator A5041033274 @default.
- W3201878242 creator A5044516598 @default.
- W3201878242 creator A5048303301 @default.
- W3201878242 creator A5051698935 @default.
- W3201878242 creator A5058492722 @default.
- W3201878242 creator A5064808332 @default.
- W3201878242 creator A5071490548 @default.
- W3201878242 creator A5073523275 @default.
- W3201878242 creator A5084835754 @default.
- W3201878242 creator A5085928090 @default.
- W3201878242 creator A5086966607 @default.
- W3201878242 creator A5090821229 @default.
- W3201878242 creator A5091696839 @default.
- W3201878242 date "2021-09-01" @default.
- W3201878242 modified "2023-09-27" @default.
- W3201878242 title "1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers" @default.
- W3201878242 doi "https://doi.org/10.1016/j.annonc.2021.08.1557" @default.
- W3201878242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8454399" @default.
- W3201878242 hasPublicationYear "2021" @default.
- W3201878242 type Work @default.
- W3201878242 sameAs 3201878242 @default.
- W3201878242 citedByCount "0" @default.
- W3201878242 crossrefType "journal-article" @default.
- W3201878242 hasAuthorship W3201878242A5005719127 @default.
- W3201878242 hasAuthorship W3201878242A5012361531 @default.
- W3201878242 hasAuthorship W3201878242A5020250473 @default.
- W3201878242 hasAuthorship W3201878242A5021244561 @default.
- W3201878242 hasAuthorship W3201878242A5028660468 @default.
- W3201878242 hasAuthorship W3201878242A5032713796 @default.
- W3201878242 hasAuthorship W3201878242A5032724752 @default.
- W3201878242 hasAuthorship W3201878242A5041033274 @default.
- W3201878242 hasAuthorship W3201878242A5044516598 @default.
- W3201878242 hasAuthorship W3201878242A5048303301 @default.
- W3201878242 hasAuthorship W3201878242A5051698935 @default.
- W3201878242 hasAuthorship W3201878242A5058492722 @default.
- W3201878242 hasAuthorship W3201878242A5064808332 @default.
- W3201878242 hasAuthorship W3201878242A5071490548 @default.
- W3201878242 hasAuthorship W3201878242A5073523275 @default.
- W3201878242 hasAuthorship W3201878242A5084835754 @default.
- W3201878242 hasAuthorship W3201878242A5085928090 @default.
- W3201878242 hasAuthorship W3201878242A5086966607 @default.
- W3201878242 hasAuthorship W3201878242A5090821229 @default.
- W3201878242 hasAuthorship W3201878242A5091696839 @default.
- W3201878242 hasBestOaLocation W32018782421 @default.
- W3201878242 hasConcept C119060515 @default.
- W3201878242 hasConcept C121608353 @default.
- W3201878242 hasConcept C126322002 @default.
- W3201878242 hasConcept C143998085 @default.
- W3201878242 hasConcept C197934379 @default.
- W3201878242 hasConcept C203014093 @default.
- W3201878242 hasConcept C22070199 @default.
- W3201878242 hasConcept C2780192828 @default.
- W3201878242 hasConcept C71924100 @default.
- W3201878242 hasConcept C8891405 @default.
- W3201878242 hasConceptScore W3201878242C119060515 @default.
- W3201878242 hasConceptScore W3201878242C121608353 @default.
- W3201878242 hasConceptScore W3201878242C126322002 @default.
- W3201878242 hasConceptScore W3201878242C143998085 @default.
- W3201878242 hasConceptScore W3201878242C197934379 @default.
- W3201878242 hasConceptScore W3201878242C203014093 @default.
- W3201878242 hasConceptScore W3201878242C22070199 @default.
- W3201878242 hasConceptScore W3201878242C2780192828 @default.
- W3201878242 hasConceptScore W3201878242C71924100 @default.
- W3201878242 hasConceptScore W3201878242C8891405 @default.
- W3201878242 hasLocation W32018782421 @default.
- W3201878242 hasLocation W32018782422 @default.
- W3201878242 hasLocation W32018782423 @default.
- W3201878242 hasOpenAccess W3201878242 @default.
- W3201878242 hasPrimaryLocation W32018782421 @default.
- W3201878242 hasRelatedWork W2020112347 @default.
- W3201878242 hasRelatedWork W2061253854 @default.
- W3201878242 hasRelatedWork W2563302682 @default.
- W3201878242 hasRelatedWork W2971392718 @default.
- W3201878242 hasRelatedWork W3037686638 @default.
- W3201878242 hasRelatedWork W3131562148 @default.
- W3201878242 hasRelatedWork W3162511055 @default.
- W3201878242 hasRelatedWork W3208258566 @default.
- W3201878242 hasRelatedWork W4294130762 @default.
- W3201878242 hasRelatedWork W4307171467 @default.
- W3201878242 hasVolume "32" @default.
- W3201878242 isParatext "false" @default.
- W3201878242 isRetracted "false" @default.
- W3201878242 magId "3201878242" @default.
- W3201878242 workType "article" @default.